Enhanced histone acetylation levels at the promoter regions of FASN have been reported to promote FASN expression and increase de novo lipid synthesis to promote tumor cell survival,[46] thus supporting its role in EBV‐miR‐BART18‐3p‐dependent CRC progression. The gene discussed is FASN; the disease is neoplasm.